Q-Line Biotech Ltd

AI

Q-Line Biotech Ltd

₹ 408 -0.83%
19 Nov - close price
About

Incorporated in 2010, Q-Line Biotech Ltd.
is engaged in the business of developing, manufacturing and marketing a diverse
range of reagents.[1]

Key Points

Business Profile:[1]
Q-Line Biotech is an Indian in-vitro
diagnostics (IVD) company engaged
in developing, manufacturing, marketing
and distributing diagnostic reagents, consumables, point-of-care (POC)
devices and diagnostic equipment.
The company primarily serves
diagnostic laboratories, hospitals
and medical colleges through
a B2B distribution-led model.

  • Market Cap ₹ 952 Cr.
  • Current Price ₹ 408
  • High / Low ₹ 735 / 396
  • Stock P/E 16.9
  • Book Value ₹ 207
  • Dividend Yield 0.00 %
  • ROCE 23.2 %
  • ROE 26.5 %
  • Face Value ₹ 10.0

Pros

  • Company has reduced debt.

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Half Yearly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2025 Sep 2025 Mar 2026 Sep 2026
216 144 198 152
171 107 135 112
Operating Profit 45 36 63 40
OPM % 21% 25% 32% 26%
20 3 2 4
Interest 8 8 11 10
Depreciation 3 4 7 8
Profit before tax 53 27 48 27
Tax % 29% 19% 26% 24%
38 22 35 20
EPS in Rs 22.11 12.61 20.74 8.67
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2025 Mar 2026 TTM
313 341 350
241 242 246
Operating Profit 72 99 103
OPM % 23% 29% 30%
17 5 6
Interest 15 19 20
Depreciation 7 11 15
Profit before tax 67 74 74
Tax % 29% 23%
47 57 56
EPS in Rs 27.76 33.35 29.41
Dividend Payout % 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -3%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 9%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: 26%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2025 Mar 2026 Sep 2026
Equity Capital 2 16 23
Reserves 188 231 460
160 213 120
99 87 76
Total Liabilities 449 547 680
91 158 141
CWIP 59 15 16
Investments 0 0 18
298 374 505
Total Assets 449 547 680

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2025 Mar 2026
22 21
-75 -29
46 36
Net Cash Flow -7 28
Free Cash Flow -48 -14
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 42% 47%

Ratios

Standalone / View Consolidated

Mar 2025 Mar 2026
Debtor Days 97 136
Inventory Days 225 258
Days Payable 139 142
Cash Conversion Cycle 183 252
Working Capital Days 52 65
ROCE % 23%

Insights

In beta
Mar 2023 Mar 2024 Mar 2025 Sep 2026
Capacity Utilization - Clinical Chemistry/Rapid/Elisa Kits (Unit 3)
%

Log in to view insights

Please log in to see hidden values.

Login
Geographic Revenue Mix - North India
%
Instrument Revenue Share
%
Number of Customers Served
count
Number of Distributors
count
Reagent Revenue Share
%
Capacity Utilization - Selectra Pro M Analyzers (Unit 2)
%
Manufacturing Capacity - Selectra Pro M Analyzers (Unit 2)
units per year
Installed Base - Selectra Pro M Analyzers
count
Product Licences Granted
count

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

May 2026Sep 2026
67.51% 67.51%
1.67% 0.88%
10.14% 8.15%
20.67% 23.45%
No. of Shareholders 3,4972,948

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents